OMP-54F28

consists of the cysteine-rich domain of Fzd8 and an immunoglobulin Fc domain; has antineoplastic actvitiy; interferes with Wnt signaling

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

1.	Neoplasms (Cancer) 02/01/2015 - "Preclinical models with OMP-54F28 have shown reduced tumor growth and decreased CSC frequency as a single agent and in combination with other chemotherapeutic agents. " 02/01/2015 - "Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28." 01/01/2019 - "Wnt inhibitors, OMP-18R5 and OMP-54F28, significantly reduced growth of HNSCC patient-derived xenografts and suppressed Wnt activation at the tumor epithelial-stromal boundary. " 02/01/2015 - "Due to these findings, a phase 1a study is nearing completion with OMP-54F28 in advanced solid tumors and 3 phase 1b studies have been opened with OMP-54F28 in combination with standard-of-care chemotherapy backbones in ovarian, pancreatic and hepatocellular cancers. "
2.	Liver Neoplasms (Liver Cancer) 02/01/2015 - "Due to these findings, a phase 1a study is nearing completion with OMP-54F28 in advanced solid tumors and 3 phase 1b studies have been opened with OMP-54F28 in combination with standard-of-care chemotherapy backbones in ovarian, pancreatic and hepatocellular cancers. "
3.	Squamous Cell Carcinoma of Head and Neck 01/01/2019 - "Wnt inhibitors, OMP-18R5 and OMP-54F28, significantly reduced growth of HNSCC patient-derived xenografts and suppressed Wnt activation at the tumor epithelial-stromal boundary. "

1.	Drug Therapy (Chemotherapy)